STAT3 and neoplasm: In contrast, therapeutic application (post-tumor inoculation) is rendered ineffective in tumor suppression due to the pre-existing activation of STAT3 in tumor cells and the production of IL-10, which inhibits the IFNγ/stat1 pathway.640 Another study revealed that while prophylactic use of TLR5 agonist flagellin promotes tumor growth, its therapeutic application inhibits it.